Madhu Kumar
Stock Analyst at Goldman Sachs
(4.50)
# 352
Out of 4,413 analysts
138
Total ratings
54.29%
Success rate
18.62%
Average return
Main Sectors:
39 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $7.33 | -18.14% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $30.85 | -15.72% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $18.13 | -6.23% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $5.28 | -24.24% | 3 | Sep 25, 2023 | |
| CERE Cerevel Therapeutics Holdings | Maintains: Neutral | $31 → $30 | $42.63 | -29.63% | 5 | May 23, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $159.67 | -2.92% | 12 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $63.37 | -16.36% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $3.62 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $23.17 | +215.06% | 8 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $46.05 | +206.19% | 9 | Apr 14, 2023 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $190 → $212 | $110.31 | +92.19% | 6 | Mar 3, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $21.97 | +54.76% | 6 | Mar 1, 2023 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $20 → $6 | $12.50 | -52.00% | 6 | Dec 9, 2022 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Sell | $8 → $14 | $27.91 | -49.84% | 6 | Nov 10, 2022 | |
| DVAX Dynavax Technologies | Maintains: Buy | $24 → $21 | $11.68 | +79.79% | 2 | Nov 4, 2022 | |
| EWTX Edgewise Therapeutics | Downgrades: Sell | $5 | $19.01 | -73.70% | 3 | Aug 25, 2022 | |
| EDIT Editas Medicine | Maintains: Sell | $10 → $8 | $5.47 | +46.25% | 4 | May 24, 2022 | |
| ARVN Arvinas | Maintains: Buy | $111 → $89 | $32.48 | +174.01% | 3 | May 24, 2022 | |
| PASG Passage Bio | Downgrades: Neutral | $29 → $6 | $1.35 | +344.44% | 1 | Jan 19, 2022 | |
| APLT Applied Therapeutics | Downgrades: Sell | n/a | $4.44 | - | 1 | Aug 27, 2021 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | n/a | $22.50 | - | 5 | Jun 23, 2021 | |
| CLLS Cellectis | Upgrades: Outperform | n/a | $2.54 | - | 2 | Mar 16, 2021 | |
| GRTS Gritstone bio | Downgrades: Underperform | n/a | $0.87 | - | 1 | Jan 20, 2021 | |
| QURE uniQure | Upgrades: Outperform | n/a | $4.57 | - | 2 | Jul 31, 2020 | |
| ABUS Arbutus Biopharma | Downgrades: Neutral | n/a | $2.69 | - | 8 | Jul 24, 2020 | |
| APRE Aprea Therapeutics | Initiates: Outperform | n/a | $5.25 | - | 1 | Apr 21, 2020 | |
| VIR Vir Biotechnology | Maintains: Underperform | n/a | $8.74 | - | 1 | Mar 27, 2020 | |
| PIRS Pieris Pharmaceuticals | Upgrades: Outperform | $400 | $11.68 | +3,324.66% | 3 | Mar 13, 2020 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | n/a | $14.96 | - | 1 | Mar 12, 2020 | |
| LPTX Leap Therapeutics | Initiates: Outperform | n/a | $3.27 | - | 1 | Feb 11, 2020 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Buy | n/a | $18.04 | - | 1 | Oct 16, 2018 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $504 | $13.27 | +3,698.04% | 3 | Oct 8, 2018 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | n/a | $149.96 | - | 2 | Aug 13, 2018 | |
| RGLS Regulus Therapeutics | Maintains: Neutral | n/a | $2.51 | - | 3 | Jul 6, 2018 | |
| DCPH Deciphera Pharmaceuticals | Downgrades: Neutral | n/a | $25.36 | - | 1 | Jun 19, 2018 | |
| IFRX InflaRx | Initiates: Buy | n/a | $1.41 | - | 1 | Feb 8, 2018 | |
| AKTX Akari Therapeutics, | Initiates: Neutral | n/a | $1.70 | - | 3 | Feb 8, 2018 | |
| TGTX TG Therapeutics | Reinstates: Buy | n/a | $15.88 | - | 1 | Dec 1, 2017 | |
| CRSP CRISPR Therapeutics AG | Initiates: Buy | n/a | $53.81 | - | 1 | Mar 28, 2017 |
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $7.33
Upside: -18.14%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $30.85
Upside: -15.72%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $18.13
Upside: -6.23%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $5.28
Upside: -24.24%
Cerevel Therapeutics Holdings
May 23, 2023
Maintains: Neutral
Price Target: $31 → $30
Current: $42.63
Upside: -29.63%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $159.67
Upside: -2.92%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $63.37
Upside: -16.36%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.62
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $23.17
Upside: +215.06%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $46.05
Upside: +206.19%
Jazz Pharmaceuticals
Mar 3, 2023
Maintains: Buy
Price Target: $190 → $212
Current: $110.31
Upside: +92.19%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $21.97
Upside: +54.76%
Iovance Biotherapeutics
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $12.50
Upside: -52.00%
Arcturus Therapeutics Holdings
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $27.91
Upside: -49.84%
Dynavax Technologies
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $11.68
Upside: +79.79%
Edgewise Therapeutics
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $19.01
Upside: -73.70%
Editas Medicine
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $5.47
Upside: +46.25%
Arvinas
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $32.48
Upside: +174.01%
Passage Bio
Jan 19, 2022
Downgrades: Neutral
Price Target: $29 → $6
Current: $1.35
Upside: +344.44%
Applied Therapeutics
Aug 27, 2021
Downgrades: Sell
Price Target: n/a
Current: $4.44
Upside: -
Intellia Therapeutics
Jun 23, 2021
Maintains: Neutral
Price Target: n/a
Current: $22.50
Upside: -
Cellectis
Mar 16, 2021
Upgrades: Outperform
Price Target: n/a
Current: $2.54
Upside: -
Gritstone bio
Jan 20, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.87
Upside: -
uniQure
Jul 31, 2020
Upgrades: Outperform
Price Target: n/a
Current: $4.57
Upside: -
Arbutus Biopharma
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.69
Upside: -
Aprea Therapeutics
Apr 21, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.25
Upside: -
Vir Biotechnology
Mar 27, 2020
Maintains: Underperform
Price Target: n/a
Current: $8.74
Upside: -
Pieris Pharmaceuticals
Mar 13, 2020
Upgrades: Outperform
Price Target: $400
Current: $11.68
Upside: +3,324.66%
Scholar Rock Holding
Mar 12, 2020
Initiates: Outperform
Price Target: n/a
Current: $14.96
Upside: -
Leap Therapeutics
Feb 11, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.27
Upside: -
EyePoint Pharmaceuticals
Oct 16, 2018
Maintains: Buy
Price Target: n/a
Current: $18.04
Upside: -
Assembly Biosciences
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $13.27
Upside: +3,698.04%
Alnylam Pharmaceuticals
Aug 13, 2018
Maintains: Buy
Price Target: n/a
Current: $149.96
Upside: -
Regulus Therapeutics
Jul 6, 2018
Maintains: Neutral
Price Target: n/a
Current: $2.51
Upside: -
Deciphera Pharmaceuticals
Jun 19, 2018
Downgrades: Neutral
Price Target: n/a
Current: $25.36
Upside: -
InflaRx
Feb 8, 2018
Initiates: Buy
Price Target: n/a
Current: $1.41
Upside: -
Akari Therapeutics,
Feb 8, 2018
Initiates: Neutral
Price Target: n/a
Current: $1.70
Upside: -
TG Therapeutics
Dec 1, 2017
Reinstates: Buy
Price Target: n/a
Current: $15.88
Upside: -
CRISPR Therapeutics AG
Mar 28, 2017
Initiates: Buy
Price Target: n/a
Current: $53.81
Upside: -